viewOpen Orphan PLC

Full interview: Open Orphan hails huge new deal leading to stronger revenues

Open Orphan (LON:ORPH) has hailed a new three-year contract with a ‘tier-one’ German pharmaceuticals company. Stepping up to Executive Chairman from CEO, Cathal Friel tells Proactive London his new role will be focussing on investor relations and 'telling the story'. He's excited about the story too, talking enthusiastically about where Open Orphan is heading now and re-capping what's happened over the last few weeks. Friel touches on the new deal saying it guarantees “significant annual revenues” with work expected to get underway this month.
Open Orphan unit Venn Life Sciences will provide the new customer pharmacokinetic services which will allow researchers to decide on dosing and assess drug side-effects.

Quick facts: Open Orphan PLC

Price: 12.9101 GBX

Market: AIM
Market Cap: £85.93 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan PLC - Proactive One2One Virtual Event

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to investors at the Proactive One2One Virtual Event. Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

3 days, 1 hour ago

2 min read